The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 105, Issue 8, 1998, Pages 882-889

  Wilton, L V ^a   Pearce, G L ^a   Martin, R M ^a   Mackay, F J ^a   Mann, R D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACRIVASTINE; ANTIASTHMATIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BUSPIRONE; CEFIXIME; CETIRIZINE; CIPROFLOXACIN; CISAPRIDE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; LAMOTRIGINE; LANSOPRAZOLE; LORATADINE; MISOPROSTOL; MOCLOBEMIDE; NEDOCROMIL; NICARDIPINE; OFLOXACIN; OMEPRAZOLE; PAROXETINE; SALMETEROL; SERTRALINE; SUMATRIPTAN; UNINDEXED DRUG; VIGABATRIN; ZOLPIDEM; ZOPICLONE;

ABORTION; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONGENITAL MALFORMATION; DRUG USE; ECTOPIC PREGNANCY; FEMALE; FETUS; FETUS DEATH; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; SPONTANEOUS ABORTION; UNITED KINGDOM;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; COHORT STUDIES; ENGLAND; FAMILY PRACTICE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; RESPIRATORY SYSTEM AGENTS;

EID: 0031696214     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1998.tb10234.x     Document Type: Article

References (16)

1. Office of Population Censuses and Surveys; Occasional paper 43. The OPCS Monitoring Scheme for Congenital Molfrirtnutions. London: HMSO, 1995.
2. Lenz W. Thalidomide and congenital abnormalities [letter]. Lancet 1962; 1:45.
3. Warkary J. Problems in applying teratologic observations in animals to man. Paediatrics 1974; 53: 820.
4. Rawlins MD, Jeffreys DB. United Kingdom Product Licence applications involving new active substances, 1987-1989: their fate after appeals. Br J Clin Pharmacol 1993; 35: 599–602.
5. Mitchell AA. Special considerations in studies of drug-induced birth defects. In: Strom, BL (editor). Pharmacoepidemiology, John Wiley: Chichester; 1994; 595–597.
6. Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol 1996; 41: 271–284.
7. Wilton L, Pearce G, Edet E, Freemantle S, Stephens MDB, Mann RD. The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Br J Urol 1996; 78: 379–384.
8. Mann RD, Wilton LV, Pearce GL, Mackay FJ, Dunn NR. Prescription-event monitoring (PEM) in 1996: a method of non-interventional observational cohort pharmacovigilance. Pharmacoepidemiol Drug Safety 1997; 6 (Suppl 3): S5–S11.
9. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Council for International Organizations of Medical Science/World Health Organization, Geneva 1993.
10. Office of Population Censuses and Surveys. Congenital malformation statistics notifications for 1992 [Series MB3 83 (No. S)]. London: HMSO, 1995.
11. Correy JF, Newman NM, Collins JA, Burrows EA, Burrows RF, Curran JT. Use of prescription drugs in the first trimester and congenital malformations. Aust NZJ Obstet Gynaecol 1991; 31: 340–344.
12. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia 1996; 37:S34–S44.
13. McAvoy BR, Kaner EFS. General practice postal surveys: a questionnaire too far. BMJ 1996; 313:732–3.
14. Kalter H, Warkany J. Congenital malformations: etiologic factors and their role in prevention. II. N Engl J Med 1983; 308:491–497.
15. Bateman DN, McElhatton P. National system for monitoring all drug use in pregnancy already exists [letter]. BMJ 1997; 314 1414–1415.
16. Craig JJ, Morrow JL. New antiepileptic drugs [letter]. BMJ 1997: 314: 603.